Neurology Specific Literature Search   
 
[home][thesaurus]
    

Differential
(Click to cross reference)
advances in neurology
adverse drug reaction
andexanet
anticoagulant, complications of
anticoagulant, reversal of
anticoagulant, treatment
anticoagulant, treatment in CVD
anticoagulation effect
apixaban
aspirin
atrial fibrillation
atrial fibrillation, risk stratification
bedridden
cerebral embolism
cerebral venous thrombosis
cerebrovascular accident
cerebrovascular accident, acute management of
cerebrovascular accident, prevention of
cerebrovascular accident, secondary prevention
cerebrovascular accident, thrombolytic agents in treatment
CHADS2
clopidogrel
complications
cost
cost effectiveness
coumarin
dabigatran
dabigatran, dose
dural sinus thrombosis
edoxaban
efficacy
embolic stroke of unknown source
enoxaparin
factor Xa inhibitor
fibrinolytic agents
fibrinolytic agents, complications
fibrinolytic therapy, selection criteria
gastrointestinal bleeding
hemorrhagic diathesis
hemostatic therapy
iatrogenic neurologic disorders
idarucizumab
intracerebral hemorrhage
intracranial hemorrhage
left ventricular dysfunction
non-vitamin K antagonist oral anticoagulants
non-vitamin K antagonist oral anticoagulants, coagulation test
old age, neurology of
partial thromboplastin time
peri-procedural
platelet inhibiting drugs
platelet inhibiting drugs, combined
practice guidelines
prevention of neurologic disorders
prothrombin time
prothrombin time, prolonged
review article
risk factors
rivaroxaban
ROCKET - AF trial
safety
thrombin inhibitor
tissue plasminogen activator, intravenous
treatment of neurologic disorder
Showing articles 0 to 18 of 18

Left Ventricular Dysfunction Among Patients with Embolic Stroke of Undetermined Source and the Effect of Rivaroxaban vs Aspirin
JAMA Neurol 78:1454-1460, Merkler, A.E.,et al, 2021

Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined Source
NEJM 378:2191-2201, Hart, R.G.,et al, 2018

Andexxa-An Antidote for Apixaban and Rivaroxaban
JAMA 320:399-400, , 2018

Intravenous tPA (Tissue-Type Plasminogen Activator) in Patients with Acute Ischemic Stroke Taking Non-Vitamin K Antagonist Oral Anticoagulants Preceding Stroke
Stroke 49:2237-2240, Jin, C.,et al, 2018

Coagulation Test Interpretation in a Patient Taking Direct Oral Anticoagulant Therapy
JAMA 320:1485-1486, Sholzberg, M. & Xu, Y., 2018

Which Oral Anticoagulation for Atrial Fibrillation?
JAMA 315:2117-2118, The Medical Letter, 2016

Risk of Gastrointestinal Bleeding Associated with Oral Anticoagulants: Population Based Retrospective Cohort Study
BMJ 350:h1585, h1679, Chang, H.Y.,et al, 2015

Comparative Risk of Gastrointestinal Bleeding with Dabigatran, Rivaroxaban, and Warfarin: Population Based Cohort Study
BMJ 350:h1857, h1979, Abraham, N.S.,et al, 2015

Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity
NEJM 373:2413-2424,2471, Siegal, D.M.,et al, 2015

Rethinking Warfarin for Atrial Fibrillation
JAMA 311:1246, Zuccott, G & Pflomm, J.M., 2014

Novel Factor Xa Inhibitor for the Treatment of Cerebral Venous and Sinus Thrombosis
Stroke 45:2469-2471, Geisbusch, C.,et al, 2014

Oral Anticoagulants and the Risk of Intracranial Hemorrhage
JAMA 312:2562-2563, Vespa, P.M., 2014

Cost-Effectiveness of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Stroke Prevention in Atrial Fibrillation
Stroke 44:1676-1681, Harringotn, A.,et al, 2013

Progress for Stroke Prevention with Atrial Fibrillation
Stroke 43:1179-1185, Katsnelson,M.,et al, 2012

Oral Antithrombotic Agents for the Prevention of Stroke in Nonvalvular Atrial Fibrillation
Stroke 43:3442-3453, Furie, K.,et al, 2012

Nonvitamin K-Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation and Previous Stroke or Transient Ischemic Attack
Stroke 43:3298-3304, Ntaios, G.,et al, 2012

New Alternative to Warfarin May Help Reduce Stroke Risk in Patients With AF
JAMA 305:25-26, Mitka,M., 2011

Rivaroxaban versus Warfarin in Nonvavular Atrial Fibrillation
NEJM 365:883-891, 952, Patel, M.R.,et al, 2011



Showing articles 0 to 18 of 18